巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Petros Pharmaceuticals

    PTPI
    0.810
    0.030
    3.57%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Petros Pharmaceuticals - 延遲價格・最後更新於 05/07 6:45
    最高位
    0.830
    最低位
    0.802
    開市價
    --
    前收市價
    0.840
    成交量(千)
    0.60
    成交額(百萬)
    0.00
    買入
    0.800
    賣出
    0.853
    每手股數
    --
    市值(百萬)
    16.75
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    5.200 - 0.646
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Petros Pharmaceuticals
    證券代碼
    PTPI.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
    發行量
    20684723
    公司總部
    1185 Avenue of the Americas, 3rd Floor
    公司網址
    https://www.petrospharma.com
    公司電話
    +1 973 242-0005
    暫無內容

    關於

    Petros Pharmaceuticals(PTPI.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
    詳細公司背景可參考: https://www.petrospharma.com